摘要
目的:探讨B细胞分化标志在119例原发中枢神经系统淋巴瘤患者预后评估中的价值。方法:采用免疫组织化学法测定BCL-2、BCL-6、CD10、MUM1/IRF4蛋白的表达,分析它们与原发中枢神经系统淋巴瘤预后的关系。结果:单因素分析显示,BCL-6+意味着更短的PFS(P=0.047)与OS(P=0.035)。多因素分析显示,BCL-6+意味着更短的PFS(HR:1.95,95%CI:1.22-3.12,P=0.005),但与OS不相关(HR:1.85,95%CI:0.71-4.8,P=0.21)。Hans分类及单个B细胞标记BCL-2、CD10、Mum1/IRF4与预后不相关。结论:BCL-6+是PCNSL的不良预后标记。
Objective： To investigate the value of B-cell differentiation markers in prognosis evaluation of 119 patients with primary CNS lymphoma（PCNSL）. Methods： The expressions of BCL-2,BCL-6,CD10 and MUM1/IRF4 protein were determined by immunohistochemistry,and their relationship with the prognosis of primary central nervous system lymphoma was analyzed. Results： Univariate analysis showed that BCL-6 positive means shorter PFS（P= 0. 047） and OS（P = 0. 035）. Multivariate analysis showed that BCL-6 positive expression was related with shorter PFS（hazard ratio：1. 95,95% CI： 1. 22-3. 12,P = 0. 005）,but did not relate with OS（ hazard ratio： 1. 85,95%CI： 0. 71-4. 80,P = 0. 21）. Classification based on Hans algorithm and expression status of the single B-cell markers BCL-2,CD10 and MUM1/IRF4 did not correlate with prognosis. Conclusion： BCL-6 may be an unfavorable prognostic biomarker for PCNSL.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2017年第5期1410-1414,共5页
Journal of Experimental Hematology
基金
温州市公益性科技计划项目(Y20150204)
